Technical Analysis for STX - Shield Therapeutics Plc

Grade Last Price % Change Price Change
F 45.25 -4.23% -2.00
STX closed down 4.23 percent on Tuesday, April 13, 2021, on 65 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up
Historical STX trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Stochastic Reached Overbought Strength -4.23%
Weak + Overbought Other -4.23%
Wide Bands Range Expansion -4.23%
Overbought Stochastic Strength -4.23%
50 DMA Support Bullish 0.33%
Upper Bollinger Band Walk Strength 0.33%
Wide Bands Range Expansion 0.33%
Overbought Stochastic Strength 0.33%
Older End-of-Day Signals for STX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Shield Therapeutics Plc Description

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Health Iron Pharmaceutical Medicine Clinic Pipe Pharmaceuticals Hospital Disease Clinical Trial Blood Pharmaceutical Industry Rtt Phosphate Clinical Research Kidney Disease Chronic Kidney Disease Design Of Experiments Anemia Inflammatory Bowel Disease

Is STX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 153.0
52 Week Low 31.75
Average Volume 1,354,717
200-Day Moving Average 88.68
50-Day Moving Average 43.77
20-Day Moving Average 39.12
10-Day Moving Average 43.73
Average True Range 3.72
ADX 29.26
+DI 26.50
-DI 15.27
Chandelier Exit (Long, 3 ATRs ) 38.36
Chandelier Exit (Short, 3 ATRs ) 42.90
Upper Bollinger Band 50.12
Lower Bollinger Band 28.13
Percent B (%b) 0.78
BandWidth 56.21
MACD Line 1.07
MACD Signal Line -0.49
MACD Histogram 1.5574
Fundamentals Value
Market Cap 53.1 Million
Num Shares 117 Million
EPS 3.60
Price-to-Earnings (P/E) Ratio 12.57
Price-to-Sales 19.50
Price-to-Book 4.04
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 51.25
Resistance 3 (R3) 51.83 50.42 50.25
Resistance 2 (R2) 50.42 48.89 50.13 49.92
Resistance 1 (R1) 47.83 47.94 47.13 47.25 49.58
Pivot Point 46.42 46.42 46.06 46.13 46.42
Support 1 (S1) 43.83 44.89 43.13 43.25 40.92
Support 2 (S2) 42.42 43.94 42.13 40.58
Support 3 (S3) 39.83 42.42 40.25
Support 4 (S4) 39.25